Erick Juarez

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

P. Pang, A. Cathcart, E. Mogalian, 2021, The New England journal of medicine.

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

A. Cathcart, E. Sarkis, W. Yeh, 2022, JAMA.

Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial

A. Cathcart, D. Falci, S. Parra, 2021, medRxiv.

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial

P. Pang, Maria L. Agostini, E. Mogalian, 2023, Open forum infectious diseases.

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab

P. Pang, A. Cathcart, N. Scott, 2021, medRxiv.

Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial

P. Pang, Maria L. Agostini, A. Nader, 2023, medRxiv.